News | September 13, 2021
Boehringer Ingelheim and Twist Bioscience ink antibody discovery collaboration
Research collaboration covers multiple antibody research programs
Research collaboration covers multiple antibody research programs
The three-dose vaccine approved for EUA contains 2mg for each dose, whereas the two-dose plan will have 3mg in each dose.
Everest gains access to a clinically validated mRNA platform and a potentially “best-in-class” mRNA COVID-19 vaccine with full technology transfer
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
Nipah virus (NiV) is an emerging zoonotic disease that causes severe disease in humans. Signs and symptoms range from asymptomatic to acute respiratory infection and fatal encephalitis
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
The company plans to enter the formulation business in January 2022. It has also opened a branch in Hyderabad to trade pharmaceutical chemicals
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The medicine is now approved for eight indications across five different types of cancer in China.
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
Subscribe To Our Newsletter & Stay Updated
